Conatus Pharmaceuticals Completes Enrollment in Phase 2n Study

Conatus Pharmaceuticals Completes Enrollment in Phase 2n Study

Conatus Pharmaceuticals said late Monday it has completed enrollment in a phase 2b study of emricasan in approximately 330 patients with biopsy-confirmed nonalcoholic steatohepatitis and stage 1 to 3 fibrosis. The primary endpoint of the study is a biopsy-based improvement in fibrosis by at least one stage compared to placebo using NASH CRN without worsening of steatohepatitis. Secondary endpoints include resolution of steatohepatitis without worsening of fibrosis, nonalcoholic fatty liver […]

Read More ˃
Cone Midstream Partners Q2 EPS Beats Street View as Revenues Fall Short

Cone Midstream Partners Q2 EPS Beats Street View as Revenues Fall Short

Cone Midstream Partners LP, a midstream energy assets company, reported Q2 net income per limited partner unit of $0.44, up from $0.39 for the same period last year, and ahead of the Capital IQ consensus forecast of $0.41. Total revenues for the quarter were $56.5 million, down from $58.4 million on the year-ago quarter, but short of he analyst forecast of $60.2 million. For full-year 2017, the company forecasts net […]

Read More ˃
European Equity Benchmarks Finish Lower

European Equity Benchmarks Finish Lower

The broad-based major European indices closed sharply lower in Friday’s trading session, as automakers, chemicals companies, and utilities providers burdened the markets. In economic news, household income per capita in the euro area increased 0.2% in Q1, after a decrease of 0.1% in the previous quarter, reported Eurostat, the statistical office of the European Union. Household real consumption per capita was stable in Q1 after an increase of 0.1% in […]

Read More ˃
Autoliv’s Target Raised by RBC

Autoliv’s Target Raised by RBC

Autoliv received a price-target boost from RBC Capital Markets despite the automotive-safety products maker’s Friday report of weaker-than-expected Q2 results, as the firm applauded the investments the company is making that weighed on its earnings. The new price target from RBC is $100 per share, up from $98. However, this is still below the stock’s Friday closing price, even after the shares fell 7.9% in Friday’s session on the Q2 […]

Read More ˃
RBC Raises Pebblebrook Hotel Trust Target

RBC Raises Pebblebrook Hotel Trust Target

Pebblebrook Hotel Trust shares were barely higher Monday morning after RBC Capital analysts raised their price target to $35 from $33 per share while reiterating an outperform rating on the stock. The broker also said it revised its FY funds from operations estimates on the real estate investment trust to reflect the sale of a parking garage at the Revere Hotel in Boston for $95 million, equal to an EBITDA […]

Read More ˃